Sex is an increasingly important feature of mouse naive pluripotent stem cells (PSCs) 
have the capacity to self-renew and maintain embryonic lineage differentiation potential in 7 culture [4] . It is of outstanding interest to understand what epigenetic and genetic mechanisms 8 influence the molecular and functional properties of PSCs. 9
Increasing evidence suggests that X-chromosome dosage can modulate the molecular and 10 functional properties of mammalian PSCs [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Female cells undergo X-chromosome 11 reactivation in the mouse inner cell mass resulting in two active X-chromosomes (XaXa), a state 12 maintained in female ESCs and induced by reprogramming to iPSCs [17] [18] [19] , reviewed in [20] . 13 XaXa is a hallmark of mouse naive pluripotency, the latter is characterized by unbiased 14 embryonic lineage differentiation potential. Consequently, XX mouse naive PSCs have a double 15 dose of X-linked genes and an increased X-to-autosome gene expression ratio compared with 16 XY cells. Work over the past decade showed that female ESCs exhibit global DNA 17 hypomethylation affecting most genomic features including imprint control regions [9] [10] [11] [12] [13] [14] [15] [16] 21] . 18 Recent work showed that female iPSCs also display global hypomethylation [22] . Differences in 19 global DNA methylation have been attributed to X-chromosome dosage since female XO cells 20 display male-like DNA methylation levels [9, 11, 13] . Female ESCs and iPSCs have genetically 21 unstable X-chromosomes, deleting part or whole X-chromosomes [9, 11, [13] [14] [15] 23, 24] . Thus, 22 mouse ESCs and iPSCs show DNA methylation and genetic loss of one X chromosome 23 associated with XaXa. 24 It was also discovered by the Heard group that female XX ESCs show increased expression of 25 several pluripotency-associated mRNAs, and display delayed pluripotency exit, indicating that 26 features of naive pluripotency are promoted in female XX ESCs [11, 25] . Differences in 27 transcription have also been attributed to X-chromosome dosage since female XO ESCs, or 28
Xist-induced X-chromosome inactivation, are associated with male-like pluripotency-associated 29 gene expression and pluripotency exit [11] . Therefore, it is important to determine the potential 30 influence of X-chromosome dosage on the molecular and functional properties of iPSCs and 31 also for mechanistic studies of reprogramming. Despite its importance, a systematic comparison 32 of transcriptional states and pluripotency exit in male and female mouse iPSCs has not yet been 33 performed. 34
While several advances have been made, the molecular pathways by which XaXa modulate 35 pluripotency remain incompletely understood [6] . At the mechanistic level, two active X-36 chromosomes inhibit MAPK and GSK3 signaling [8, 11] , and global DNA hypomethylation has 37 been attributed to reduced expression of DNMT3A and DNMT3B [9] , or DNMT3L [10], or 38 UHRF1 [13, 15, 22] in female ESCs/iPSCs. More recently, it was discovered that increased 39 dosage of the X-linked MAPK inhibitor Dusp9 (dual-specificity phosphatase 9) is in part 40 responsible for inhibiting DNMT3A/B/L and global DNA hypomethylation in female ESCs [13] . 41
The expression level of Dusp9 is higher in XX ESCs than in XY ESCs and overexpression of 1 Dusp9 in male ESCs induced female-like global DNA hypomethylation. Conversely, 2 heterozygous deletion of Dusp9 in female ESCs restored male-like global DNA methylation, 3 suggesting that Dusp9 is responsible for MAPK-mediated DNMT3A/B repression in female 4
ESCs. However, whether Dusp9 heterozygous deletion in female ESCs has effects on the 5 transcriptional regulatory network and pluripotency exit has not yet been explored. Furthermore, 6 how and which X-linked genes modulate the pluripotency regulatory network of naive PSCs 7 remains unclear [6] . In addition, novel insights may be gained by identification of cis-regulatory 8 elements that drive sex-specific pluripotent stem cell states. 9
Here, in order to investigate the influence of X-chromosome dosage on iPSCs, we 10 systematically compared male and female mouse iPSCs at different passage and at the 11 transcriptional, pluripotency exit, cell growth and X-chromosome dosage level. We found that 12 sex-specific differences in cell growth, transcription and pluripotency exit are established late 13 during iPSC reprogramming and subsequently resolved as a result of X-chromosome loss in 14 female iPSCs upon passage. We further investigated the regulatory landscape of male and 15 female ESCs using genome-wide chromatin accessibility analyses. We found that thousands of 16 chromatin regions differ in accessibility in male and in female ESCs. Figure 1A ) [26] . After two weeks of doxycycline (dox) treatment 38 to induce reprogramming, 10 female and 11 male iPSC lines were expanded on feeders in the 39 presence of serum and LIF (S/L) in the absence of dox ( Figure 1A ), or adapted to dual 40 ERK/GSK3 inhibition and LIF conditions (2i/L) ( Figures S1A-E We asked whether sex affects iPSCs growth. We counted the number of male and female 9 iPSCs over two days starting from the same amount of cells. We found that all our early 10 passage female iPSC lines grew slower than male iPSCs, with a doubling time (Td) extended by 11 ˜3.4 hours compared with male iPSCs grown in S/L (Td female=18.4.±1.5hr vs Td 12 male=15.0±0.9hr) ( Figure 1C ). Similarly, we found that female ESCs grew slower than male 13 ESCs ( Figure 1C ). The sex-specific difference in iPSCs and ESCs growth did not depend on 14 culture conditions because female ESCs and iPSCs still grew slower than male cells in 2i/LIF 15 ( Figure S1F Using reverse transcription (RT) quantitative real-time PCR (qPCR) we found that in S/L, all our 21 early passage female iPSC lines consistently expressed higher levels of pluripotency-22 associated genes Prdm14, Nanog and Tcl1 compared with male iPSCs ( Figure 1D ). Western 23 blot analysis showed that female iPSCs had increased NANOG protein levels compared with 24 male iPSCs ( Figure 1E ). These differences closely resemble those of mouse ESCs [11, 13] , in 25 agreement with the notion that iPSCs are molecularly equivalent to ESCs. Thus, reprogramming 26 to iPSCs results in sex-specific differences in pluripotency-associated gene expression. 27 28 Next, prompted by the differences in pluripotency gene expression, we investigated the extent 29 to which sex affects exit from pluripotency in iPSCs. We subjected female and male iPSCs to 30 LIF withdrawal-mediated differentiation and measured the downregulation of pluripotency-31 associated genes by RT-qPCR. Exit from pluripotency was delayed in female iPSCs for 32
Prdm14, Nanog and Tcl1 ( Figure 1F ). We confirmed these results using an alternative 33 differentiation protocol that mimics epiblast differentiation (Figures S1E, S1G-I) [11, 29] chromosome loss in our iPSC lines, we designed a simple qPCR assay in which the 7 X/autosome genomic DNA ratio is determined by measuring four X-linked genes (Tfe3, Bcor, 8
Pdha1 and Mid1, located on either distal region on the X-chromosome, Figure 1G , bottom) and 9 one autosomal gene (Gapdh). We found that female iPSCs at late passage were consistently 10 losing one of the two X-chromosomes, and termed these cells XO iPSCs ( Figure 1G ). These 11 results were in agreement with an independent assay using RNA in situ-hybridization for X- 1F) all correlated with the presence of two active X-chromosomes. Collectively, these results 15
indicate that sex-specific differences in growth rates, transcription and pluripotency exit are 16 induced in iPSCs as a result of X-chromosome reactivation in female iPSCs, but are lost upon 17 passage concomitant with X-chromosome loss in female iPSCs. 18 19 What might be the functional relevance of sex-specific differences in cell growth? Female 20 mouse and human embryos show a delay in post-implantation development that has been 21 attributed to the presence of two X-chromosomes in female cells [28] . It has been suggested 22 that the presence of two X-chromosomes slows down development to ensure that cells progress 23 through X-chromosome inactivation [11] . We sought to test, in vitro, the hypothesis that reduced 24 X-chromosome dosage provides a competitive growth advantage to cells that have undergone 25 X-chromosome inactivation. We mixed XX ESCs and GFP-labelled XY ESCs in different ratios 26 and followed the proportion of labeled cells over time. We found that the increased cell growth 27 of male ESCs can provide a small advantage over a 8 day period ( Figure S1K ). We conclude 28 that female mouse PSCs with two active X-chromosome recapitulate the growth delay of the 29 early postimplantation female mammalian embryo. 30
Eras, Dkc1, Otud6a, Fhl1, Zfp185 and Scml2 Dosage Do Not Explain Sex-Specific 31
Differences in Pluripotency Exit 32
We sought to find the X-linked regulators that drive stabilization of pluripotency in female PSCs. 33 We analyzed RNA sequencing (RNA-seq) and published proteomics data of male and female 34
ESCs [13] . We selected X-linked candidate factors based on increased expression in female 35 ESCs, and evidence that the genes are subject to X-chromosome inactivation (Tables S1/S2 In order to identify the putative target genes, we searched for genes associated with open 1 chromatin regions enriched for specific motifs, then determined the target genes shared for 2 open chromatin containing more than one motif. We found that 574 genes were associated with 3 binding motifs for all three motifs KLF, ESRRB and SOX2 ( Figure 3D ). These genes contained 4
Prdm14. Thus, upregulation of Prdm14 mRNA in female ESCs is associated with increased 5 chromatin accessibility at genomic regions that contain multiple pluripotency-associated TF 6 motifs. We sought to carry out a similar analysis for chromatin more open in male ESCs and 7 identified 213 genes associated with both JUN/AP-1 and TEAD motifs. These genes included 8 the early ectodermal gene Krt18 and essential neurogenesis related gene Sox11, which were 9 more expressed in male ESCs than in female ESCs. Taken together, these analyses allowed 10 the identification of TFs that regulate a large number of cis-regulatory regions, thereby 11 improving our understanding on how sex can drive two distinct pluripotent stem cell states. 12 Figure 5C ). We corroborated this finding using unsupervised 5 clustering of the most variable genes between all 4 cell types, where Dusp9+/-ESCs clustered 6 together with Dusp9+/+ ESCs, and away from XY ESCs ( Figure 5D ). Nanog which maintained a female-like pattern in Dusp9+/-ESCs during pluripotency exit 37 ( Figure 5H , Table S7 ). We validated the expression of Prdm14 and Nanog using RT-qPCR 38 analyses ( Figure 5I ESCs. Moreover, using genome editing we found that sex-specific differences in pluripotency 22 exit and cell growth can be molecularly uncoupled from DNA methylation. 23
Zic3 Dosage Does Not Modulate Sex-Specific Differences in Transcription and

Impact of Sex and X-chromosome Dosage on Growth, Transcription and Pluripotency 24
Exit 25
One outcome of our study is that the number of active X-chromosomes correlates with sex-26 specific differences in growth, transcription and pluripotency exit in iPS cells (Figure 1 ), in 27 addition to differences in DNA methylation [22] . Reprogramming somatic cells to iPSCs is an 28 important system to study erasure of epigenetic memory and pluripotency. Sex does not appear 29 to influence the efficiency of iPSCs generation, since we previously showed that male and 30 female cells reprogram with similar efficiencies in this system [30] . However, we have now 31
established that the presence of two active X-chromosomes as a result of reprogramming to 32 pluripotency in female cells is associated with slower growth in iPSCs, increased pluripotency-33 associated gene expression, and delayed pluripotency exit. These differences are likely caused 34 by changes in X-chromosome dosage, consistent with previous discoveries in mouse ESCs 35 [6, 9, 11, 14] , in human ESCs [7, 8, 58] and in postimplantation mammalian embryos [6, 28, 59 ]. The 36 notion that X-chromosome dosage influences the molecular and functional properties of iPSCs 37 [6, 11, 22] is further supported by the loss of sex-specific differences concomitant with loss of one 38 X-chromosome in female iPSCs, in agreement with previous observations in ESCs [9, 11, 13 ,14] 39 and in iPSCs. The important point is that studies of reprogramming to iPSCs should consider 40 the number of active X-chromosomes as a modulator of the transcriptional and growth states of 1 iPSCs and cells of different sex should always be studied separately, but also often both 2 considered. 3
The presence of two X-chromosomes has been associated with delayed embryo post-4 implantation growth in several mammalian species [28, 59 ]. Here we show for the first time that 5 this property is recapitulated in mouse ESCs and iPSCs, where XX ESCs grow slightly, and 6 significantly slower than XY and XO ESCs (Figure 1 ). Since the growth differences are 7 maintained after dual GSK3B and ERK inhibition, additional pathways are likely involved. One 8 hypothesis is that there could be a competitive growth advantage of cells that have undergone 9
X-chromosome inactivation in the post-implantation mammalian embryo to select against 10 remaining cells with two active X-chromosomes that fail to undergo X-chromosome inactivation. 11
Our in vitro experiment suggests that X-chromosome inactivation could indeed provide a small 12 growth advantage. However, this hypothesis remains to be tested in vivo. 13
Impact of Dusp9 Dosage on Pluripotent States 14
A previous study showed that Dusp9 modulates DNA hypomethylation in female mouse ESCs 15
[13]. However, the effects of reducing Dusp9 dosage in XX ESCs on growth, transcription and 16 pluripotency exit were unknown. An important outcome of our analyses is that female Dusp9 17 heterozygous XX ESCs display male-like global DNA methylation levels and maintain female-18 like growth and delayed pluripotency exit ( Figure 5 ). 
EXPERIMENTAL PROCEDURES 28
Mice and reprogramming 29
MEFs were isolated from individual E14.5 mouse embryos obtained from a cross between wild 30 type (WT) C57BL/6 and homozygous Rosa26:M2rtTA, TetO-OSKM mice [26] . Individual 31 embryos were genotyped for sex using Ube1 as previously described (See Table S8 BioReagents, BP2647100) on DR4 feeders in ESC medium for two days starting from 24h after 7 transfection, and expanded at low density on WT feeders in 10cm dishes. Individual colonies 8
were picked onto WT feeders, expanded for another two passages and genotyped for both WT 9 and mutant alleles (primers in Genomic DNA extraction and qPCR 8 Genomic DNA (gDNA) was extracted from feeder-depleted ESCs and iPSCs using the PureLink 9
Genomic DNA Kit (Invitrogen, K1820) and qPCR was performed using the Platinium SYBR 10
Green qPCR SuperMix-UDG kit (Invitrogen, 11733046) on a ABI ViiA7 real-time PCR system 11 (Applied Biosystems), following the manufacturer's protocol. Primers against four X-linked 12 genes (Tfe3, Bcor, Pdha1, and Mid1) covering the two distal parts of the mouse X-chromosome 13 are listed in Table S8 ( Figure 1G ). The standard curve was derived from serial dilutions of gDNA 14 from XY ESCs (V6.5). All qPCR assays used had an efficiency above 95%. 
RT-qPCR 21
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, 74106) or TRIzol (Invitrogen,  22 15596026). cDNA synthesis was performed using the SuperScript III First-Strand Synthesis 23
SuperMix kit (Invitrogen, 11752-050) and RT-qPCR was performed using the Platinium SYBR 24
Green qPCR SuperMix-UDG kit (Invitrogen, 11733046) and on the ABI ViiA7 real-time PCR 25 system, following the manufacturer's protocol. Primers used are listed in female ESCs) at 0h and 24h of EpiLC differentiation were used for unsupervised clustering 35 comparison, which was performed in R with heatmap.2 function in package "gplots". 36
RNA sequencing 37
Total RNA was isolated from two independent female Dusp9+/-ESC lines, Dusp9+/+ XX and 38 XY ESCs in both the undifferentiated state and the differentiated state after 24 hours of LIF 39 withdrawal using TRIzol following the manufacturer's protocol. 4 µg of total RNA was used for 1 construction of stranded poly(A) mRNA-Seq library with the KAPA stranded mRNA Library prep 2 kit (KAPA Biosystems, KK8421). Library concentrations were quantified with the Qubit dsDNA 3 HS (High Sensitivity) Assay Kit (Invitrogen, Q32854), and equimolar amounts were pooled for 4 single-end sequencing on an Illumina HiSeq 4000 instrument (Illumina) to yield ~20 million 5 (range 16-23 million) 36bp long reads per sample. 6
Differential gene expression analysis 7
Reads from all datasets (Dusp9+/-ESCs, Dusp9+/+ ESCs and XY ESCs) were aligned to 8 mouse reference genome GRCm38/mm10 using STAR (v2.5.3a) with default parameters 9 followed with conversion to BAM format sorted by coordinate. The mapping efficiencies of the 10 datasets were >69% of uniquely mapped reads. Subsequently, the featureCounts function from 11 the R Bioconductor package "Rsubread" was used to assign mapped reads to genomic 12 features. For downstream analyses, only the genes with CPM value (count-per-million) higher 13 than 0.5 in at least two libraries were retained. The resulting read count matrix (Table S5) were corrected for multiple testing with the Benjamini-Hochberg method to control the FDR. 17 DEGs were defined on the basis of both FDR < 0.05 and fold difference ≧
Venn diagrams 18
were generated using an online tool as previously described [72] . Heatmaps were created using 19 unsupervised hierarchical clustering of both 200 most variable genes and the different samples 20 and generated in R using the heatmap.2 function of the package "gplots". 21
Definition of pluripotency exit delay 22
In order to quantitatively measure the pluripotency exit delay in Dusp9+/+ ESCs, XY ESCs and 23 Dusp9+/-ESCs, an expression matrix containing genes related to stem cell maintenance 24 (GO0019827) and stem cell development (GO0048864) with normalized counts was created. 25
The ratio of expression level at 24h to 0h of differentiation (24h/0h ratio) was calculated for both 26 WT XY and Dusp9+/+ ESCs. Only the genes that were downregulated in XY ESCs and had 27 24h/0h ratios < 0.75 passed the filtering. Subsequently, 24h/0h ratios were compared between 28 WT XX and XY ESCs, if the resulting value was >1, the gene was qualified as a "delayed" gene 29 during the pluripotency exit in Dusp9+/+ ESCs. For these genes, the same algorithm was 30 applied to evaluate the delay in Dusp9+/-ESCs. 31
Differential chromatin accessibility analysis 32 ATAC-seq data for mouse XX ESCs and XY ESCs were retrieved from a previous collection 33 (accession numbers are GSM2247118 and GSM2247119 in XX and XY ESCs, respectively) 34 [32] . Single-end-reads raw data were analyzed using the ATAC-seq pipeline from the Kundaje 35 lab (Version 0.3.3) [73] . Briefly, the raw reads were first trimmed using cutadapt (version 1.9.1) 36 to remove adaptor sequence at the 3′ end. The trimmed reads were aligned to reference 37 genome (mm10) using Bowtie2 (v2.2.6) using the '--local' parameter. Single-end reads that 38 aligned to the genome with mapping quality ≥ 30 were kept as usable reads (reads aligned to the 39 mitochondrial genome were removed) using SAMtools (v1.2). PCR duplicates were removed 1 using Picard's MarkDuplicates (Picard v1.126). Open chromatin regions (peak regions) were 2 called using MACS2 (v2.1.0) using the '-g 1.87e9 -p 0.01 --nomodel --shift -75 --extsize 150 -B -3 -SPMR --keep-dup all --call-summits' parameter [74] . The differential chromatin accessibility 4 analysis and related plots were performed using the DiffBind package using the 'summits=250, 5 default DESeq2, log2fold=1, FDR<=0.05' parameter [75] . GO analysis for Biological Process 6 terms was performed using GREAT (v3.0.0) analysis [76] with the mm10 reference genome, 7
where each region was assigned to the single nearest gene within 1000kb maximum distance to 8 the gene's TSS. 9
Motif Discovery Analysis 10
Known motif search was performed using program of findMotifsGenome.pl in the HOMER 11 package (v4. 
Statistical analysis 36
Statistical tests were performed using the Graphpad Prism 5 software (GraphPad Software). 37 Unpaired two-tailed t-test, one-way ANOVA with Dunnett's multiple comparisons test or two-way 38 repeated-measures ANOVA were used as indicated. All data are presented as the mean±SEM. 39
p-values <0.05 were considered statistically significant. 40
Data Availability 1
The ATAC-seq data discussed in this publication have been deposited in NCBI's Gene 2 Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession 3 number GSM2247118 and GSM2247119. The GEO accession number for the RNA-seq data 4 reported in this paper is GSE110215. 5
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